H.C. Wainwright has revised its price target for Personalis (PSNL, Financial), boosting it from $8 to $9, while maintaining a Buy rating on the stock. This decision comes in response to the company's impressive revenue performance, as communicated to investors in a recent research update. The firm has adjusted its projections to account for Personalis' continued growth and an optimistic Q2 revenue guidance range that surpassed previous expectations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Personalis Inc (PSNL, Financial) is $7.33 with a high estimate of $9.00 and a low estimate of $5.00. The average target implies an upside of 83.33% from the current price of $4.00. More detailed estimate data can be found on the Personalis Inc (PSNL) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Personalis Inc's (PSNL, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Personalis Inc (PSNL, Financial) in one year is $2.18, suggesting a downside of 45.5% from the current price of $4. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Personalis Inc (PSNL) Summary page.
PSNL Key Business Developments
Release Date: May 06, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Personalis Inc (PSNL, Financial) achieved revenues of over $20 million in Q1 2025, with a significant increase in molecular tests delivered.
- The company is well-positioned in the growing MRD market, expected to mature into a $20 billion market.
- Personalis Inc (PSNL) reported strong biopharma revenue growth, driven by the adoption of their Next Personal test.
- The company has a strong cash position with $185.7 million in cash and equivalents, providing a comfortable runway for growth.
- Personalis Inc (PSNL) is making significant progress in clinical usage and reimbursement efforts, with positive feedback from physicians and high retention rates.
Negative Points
- Despite revenue growth, Personalis Inc (PSNL) reported a net loss of $15.8 million for Q1 2025.
- The company faces challenges with unreimbursed clinical test costs impacting gross margins.
- There is uncertainty around the timing and outcome of reimbursement decisions, which could affect future revenue.
- Personalis Inc (PSNL) is experiencing some headwinds in the pharmaceutical market due to government trade issues and project deferrals.
- The company is still in the early stages of data maturation and publication for certain cancer indications, which could delay reimbursement submissions.
